CL2021002847A1 - Terapias de combinación que comprenden inhibidores de apremilast y tyk2 - Google Patents

Terapias de combinación que comprenden inhibidores de apremilast y tyk2

Info

Publication number
CL2021002847A1
CL2021002847A1 CL2021002847A CL2021002847A CL2021002847A1 CL 2021002847 A1 CL2021002847 A1 CL 2021002847A1 CL 2021002847 A CL2021002847 A CL 2021002847A CL 2021002847 A CL2021002847 A CL 2021002847A CL 2021002847 A1 CL2021002847 A1 CL 2021002847A1
Authority
CL
Chile
Prior art keywords
apremilast
combination therapies
tyk2 inhibitors
tyk2
inhibitors
Prior art date
Application number
CL2021002847A
Other languages
English (en)
Spanish (es)
Inventor
Peter Henry Schafer
Robert Plenge
Mary Adams
Lisa Beebe
Gilles Buchwalter
Tiffany Carr
Te-Chen Tzeng
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of CL2021002847A1 publication Critical patent/CL2021002847A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
CL2021002847A 2019-04-30 2021-10-29 Terapias de combinación que comprenden inhibidores de apremilast y tyk2 CL2021002847A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2019/029772 WO2020222773A1 (en) 2019-04-30 2019-04-30 Combination therapies comprising apremilast and tyk2 inhibitors

Publications (1)

Publication Number Publication Date
CL2021002847A1 true CL2021002847A1 (es) 2022-07-22

Family

ID=66476870

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021002847A CL2021002847A1 (es) 2019-04-30 2021-10-29 Terapias de combinación que comprenden inhibidores de apremilast y tyk2

Country Status (14)

Country Link
EP (2) EP3962475A1 (zh)
JP (2) JP2022537877A (zh)
KR (2) KR20220002488A (zh)
CN (2) CN114269336A (zh)
AU (2) AU2019443366A1 (zh)
BR (2) BR112021021809A2 (zh)
CA (2) CA3138473A1 (zh)
CL (1) CL2021002847A1 (zh)
CO (2) CO2021015614A2 (zh)
IL (2) IL287665A (zh)
MA (1) MA55799A (zh)
MX (2) MX2021013317A (zh)
SG (2) SG11202112043PA (zh)
WO (2) WO2020222773A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019443366A1 (en) 2019-04-30 2021-12-02 Celgene Corporation Combination therapies comprising apremilast and Tyk2 inhibitors
KR20230159421A (ko) 2021-02-19 2023-11-21 수도 바이오사이언시즈 리미티드 Tyk2 억제제 및 이의 용도
IL311624A (en) * 2021-09-23 2024-05-01 Bristol Myers Squibb Co Methods for treating hair loss disorders with TYK2 inhibitors
IL312330A (en) 2021-10-25 2024-06-01 Kymera Therapeutics Inc TYK2 joints and their uses

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
GB0709031D0 (en) 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
AR076550A1 (es) * 2009-05-06 2011-06-22 Portola Pharm Inc Inhibidores de la janus tirosina kinasa (jak)
WO2012062704A1 (en) 2010-11-09 2012-05-18 Cellzome Limited Pyridine compounds and aza analogues thereof as tyk2 inhibitors
KR101889757B1 (ko) * 2011-04-28 2018-08-20 셀진 코포레이션 자가 면역 및 염증 질환의 치료 및 관리를 위한 ｐｄｅ4 저해제를 이용한 방법 및 조성물
UA113750C2 (xx) 2011-12-27 2017-03-10 Склад (+)-2-$1-(3-етокси-4-метоксифеніл)-2-метансульфонілетил]-4-ацетиламіноізоіндолін-1,3-діону
JP6109192B2 (ja) 2012-01-10 2017-04-05 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ピリダジンアミド化合物及びｓｙｋ阻害剤としてのそれらの使用
WO2013146963A1 (ja) 2012-03-28 2013-10-03 武田薬品工業株式会社 複素環化合物
CA2875990A1 (en) 2012-05-24 2013-11-28 Cellzome Limited Heterocyclyl pyrimidine analogues as tyk2 inhibitors
EP2922846B1 (en) * 2012-11-08 2018-10-03 Bristol-Myers Squibb Company Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn-alpha
US9540333B2 (en) * 2012-11-08 2017-01-10 Bristol-Myers Squibb Company Alkyl amide-substituted pyrimidine compounds useful in the modulation of IL-12, IL-23 and/or IFNα
NZ628320A (en) * 2013-03-14 2017-04-28 Celgene Corp Treatment of psoriatic arthritis using apremilast
WO2015016206A1 (ja) 2013-07-30 2015-02-05 武田薬品工業株式会社 複素環化合物
CN105793245B (zh) 2013-09-03 2018-03-20 萨勒姆有限公司 药物化合物
TWI582077B (zh) 2013-11-07 2017-05-11 必治妥美雅史谷比公司 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物
US10273237B2 (en) 2013-12-10 2019-04-30 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN-α responses
WO2015091584A1 (en) 2013-12-18 2015-06-25 F. Hoffmann-La Roche Ag Thiazolopyridine compounds, compositions and their use as tyk2 kinase inhibitors
WO2015123453A1 (en) 2014-02-14 2015-08-20 Portola Pharmaceuticals, Inc. Pyridazine compounds as jak inhibitors
JP6526065B2 (ja) 2014-02-28 2019-06-05 ニンバス ラクシュミ， インコーポレイテッド Ｔｙｋ２阻害剤およびその使用
EP3157520B1 (en) 2014-06-23 2019-09-04 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality
WO2016025686A1 (en) * 2014-08-15 2016-02-18 Celgene Corporation Dosage titration of apremilast for the treatment of diseases ameliorated by pde4 inhibition
NO2721710T3 (zh) 2014-08-21 2018-03-31
WO2016047678A1 (ja) 2014-09-25 2016-03-31 武田薬品工業株式会社 複素環化合物
TWI788655B (zh) 2015-02-27 2023-01-01 美商林伯士拉克許米公司 酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途
JP6802263B2 (ja) 2015-09-02 2020-12-16 ニンバス ラクシュミ， インコーポレイテッド Ｔｙｋ２阻害剤およびその使用
HUE049305T2 (hu) 2016-02-24 2020-09-28 Pfizer Pirazolo[1,5-a]pirazin-4-il származékok mint JAK-inhibitorok
US10836770B2 (en) 2016-10-07 2020-11-17 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or INF alpha responses
JP7082130B2 (ja) 2016-10-14 2022-06-07 ニンバス ラクシュミ， インコーポレイテッド Ｔｙｋ２阻害剤およびその使用
AU2017345736B2 (en) 2016-10-21 2022-04-07 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof
EP3532473B1 (en) 2016-10-28 2021-09-29 Bristol-Myers Squibb Company Heterobicyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
US11299494B2 (en) 2016-11-17 2022-04-12 Bristol-Myers Squibb Company Substituted imidazo[1,2-b]pyridazines as interleukin-23 and interferon-α modulators
GB2562702B (en) 2017-03-06 2022-05-18 Linear Shaped Ltd Frame and linear shaped charge
IL269036B2 (en) * 2017-03-08 2023-03-01 Nimbus Lakshmi Inc tyk2 inhibitors, uses and methods for their production
AU2019443366A1 (en) 2019-04-30 2021-12-02 Celgene Corporation Combination therapies comprising apremilast and Tyk2 inhibitors

Also Published As

Publication number Publication date
JP2022537877A (ja) 2022-08-31
CO2021015622A2 (es) 2022-02-28
WO2020222773A1 (en) 2020-11-05
CA3138473A1 (en) 2020-11-05
MX2021013317A (es) 2022-01-18
CN114206333A (zh) 2022-03-18
MX2021013318A (es) 2022-01-31
EP3962475A1 (en) 2022-03-09
EP3962476A1 (en) 2022-03-09
AU2019443366A1 (en) 2021-12-02
KR20220002488A (ko) 2022-01-06
CN114269336A (zh) 2022-04-01
CA3138686A1 (en) 2020-11-05
CO2021015614A2 (es) 2021-12-10
WO2020223431A1 (en) 2020-11-05
JP2022537878A (ja) 2022-08-31
AU2020266143A1 (en) 2021-12-02
BR112021021826A2 (pt) 2022-01-04
BR112021021809A2 (pt) 2022-01-04
KR20220002489A (ko) 2022-01-06
SG11202112018YA (en) 2021-11-29
JP7453251B2 (ja) 2024-03-19
BR112021021826A8 (pt) 2022-06-21
SG11202112043PA (en) 2021-11-29
IL287665A (en) 2022-07-01
MA55799A (fr) 2022-03-09
IL287670A (en) 2021-12-01

Similar Documents

Publication Publication Date Title
CO2021015614A2 (es) Terapias de combinación que comprenden inhibidores de apremilast y tyk2
BR112021017495A2 (pt) Derivado de pirazina e sua aplicação na inibição de shp2
CL2021000382A1 (es) Compuestos novedosos de sulfonamidaurea
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
MX2018005600A (es) Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello.
BR112018001640A2 (pt) combinação de antagonista da pd-1 com um inibidor de egfr
CR20220325A (es) Fluoroalquil-oxadiazoles y sus usos
BR112015010477A2 (pt) combinação farmacêutica que compreende um inibidor b-raf e um inibidor de histona desacetilase e o uso dos mesmos no tratamento de doenças proliferativas
BR112015026021A2 (pt) terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer
ZA202103429B (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
EA201790907A1 (ru) Новые производные пиразолопиримидина в качестве ингибиторов nik
ECSP22044525A (es) Terapia de combinaci?n que comprende un inhibidor de alk2 y un inhibidor de jak2
BR112021018739A8 (pt) Composições e métodos para o tratamento de doenças ou distúrbios associados a kras
BR112022001270A2 (pt) Compostos inibidores
EA201691555A1 (ru) Способы лечения и предотвращения заболеваний почек и жировых дистрофий печени
MX2018008903A (es) COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA.
BR112023000687A2 (pt) Métodos e combinações de inibidores de kat6 para o tratamento de câncer
BR112023015210A2 (pt) Inibidores de cdk2 e métodos de uso dos mesmos
BR112022011892A2 (pt) Composições farmacêuticas intranasais de inibidores de cgrp
EA202191955A1 (ru) Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы
CL2022001006A1 (es) Inhibidores de tim-3 y sus usos
AR116024A1 (es) Métodos de tratamiento de enfermedades neurodegenerativas
EA201990508A1 (ru) ИНГИБИРОВАНИЕ АКТИВНОСТИ Olig2
BR112022008580A2 (pt) Métodos para tratar transtornos depressivos
CL2021000282A1 (es) Inhibidores de ckd8/19